Literature DB >> 29625968

2018 update of the EULAR recommendations for the management of Behçet's syndrome.

Gulen Hatemi1, Robin Christensen2, Dongsik Bang3, Bahram Bodaghi4, Aykut Ferhat Celik5, Farida Fortune6, Julien Gaudric7, Ahmet Gul8, Ina Kötter9, Pietro Leccese10, Alfred Mahr11, Robert Moots12, Yesim Ozguler1, Jutta Richter13, David Saadoun14,15,16,17, Carlo Salvarani18, Francesco Scuderi19, Petros P Sfikakis20, Aksel Siva21, Miles Stanford22, Ilknur Tugal-Tutkun23, Richard West24, Sebahattin Yurdakul1, Ignazio Olivieri25, Hasan Yazici1.   

Abstract

Several new treatment modalities with different mechanisms of action have been studied in patients with Behçet's syndrome (BS). The aim of the current effort was to update the recommendations in the light of these new data under the auspices of the European League Against Rheumatism (EULAR) Standing Committee for Clinical Affairs. A task force was formed that included BS experts from different specialties including internal medicine, rheumatology, ophthalmology, dermatology, neurology, gastroenterology, oral health medicine and vascular surgery, along with a methodologist, a health professional, two patients and two fellows in charge of the systematic literature search. Research questions were determined using a Delphi approach. EULAR standardised operating procedures was used as the framework. Results of the systematic literature review were presented to the task force during a meeting. The former recommendations were modified or new recommendations were formed after thorough discussions followed by voting. The recommendations on the medical management of mucocutaneous, joint, eye, vascular, neurological and gastrointestinal involvement of BS were modified; five overarching principles and a new recommendation about the surgical management of vascular involvement were added. These updated, evidence-based recommendations are intended to help physicians caring for patients with BS. They also attempt to highlight the shortcomings of the available clinical research with the aim of proposing an agenda for further research priorities. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  anti-tnf; behcet’s disease; treatment

Mesh:

Substances:

Year:  2018        PMID: 29625968     DOI: 10.1136/annrheumdis-2018-213225

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  140 in total

1.  Pathergy phenomenon: an important clinical pointer to Behҫet disease.

Authors:  Dharmagat Bhattarai; Pandiarajan Vignesh; Deepti Suri; Anju Gupta
Journal:  BMJ Case Rep       Date:  2019-06-24

Review 2.  Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.

Authors:  Marko Barešić; Mirna Reihl; Mario Habek; Nenad Vukojević; Branimir Anić
Journal:  Rheumatol Int       Date:  2018-05-17       Impact factor: 2.631

3.  Budd-Chiari Syndrome in Behçet's Disease successfully managed with immunosuppressive and anticoagulant therapy: A case report and literature review.

Authors:  Christian Mario Amodeo Oblitas; Francisco Galeano-Valle; Neera Toledo-Samaniego; Blanca Pinilla-Llorente; Jorge Del Toro-Cervera; Arturo Álvarez-Luque; Alejandra García-García; Pablo Demelo-Rodriguez
Journal:  Intractable Rare Dis Res       Date:  2019-02

4.  Pattern of pulmonary vasculitis and major vascular involvement in Hughes-Stovin syndrome (HSS): brief report of eight cases.

Authors:  Yasser Emad; Yasser Ragab; Ossama Ibrahim; Ahmed Saad; Johannes J Rasker
Journal:  Clin Rheumatol       Date:  2019-12-18       Impact factor: 2.980

5.  Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics.

Authors:  Jurgen Sota; Donato Rigante; Giacomo Emmi; Giuseppe Lopalco; Ida Orlando; Gian Marco Tosi; Bruno Frediani; Antonio Vitale; Silvana Guerriero; Florenzo Iannone; Lorenzo Vannozzi; Claudia Fabiani; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2020-02-01       Impact factor: 3.397

Review 6.  Behcet's disease with peripheral nervous system involvement successfully treated with golimumab: a case report and review of the literature.

Authors:  Menghui Yao; Congcong Gao; Chunyi Zhang; Xueqi Di; Wenfang Liang; Wenbo Sun; Qianqian Wang; Zhaohui Zheng
Journal:  Rheumatol Int       Date:  2020-07-16       Impact factor: 2.631

7.  A study of the use of Behçet/Behçet's disease or syndrome with or without Adamantiades in the medical literature during the past two decades.

Authors:  Yaşar Barış Turgut; Gökhan Sargın
Journal:  Eur J Rheumatol       Date:  2020-11-19

Review 8.  Optic neuritis as a presenting feature of Behçet's disease: case-based review.

Authors:  Željka Kardum; Jasminka Milas Ahić; Ana Marija Lukinac; Ružica Ivelj; Višnja Prus
Journal:  Rheumatol Int       Date:  2020-08-29       Impact factor: 2.631

Review 9.  Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review.

Authors:  Winifred Ekezie; Rachael L Murray; Sanjay Agrawal; Ilze Bogdanovica; John Britton; Jo Leonardi-Bee
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

Review 10.  Behçet Disease: An Update for Dermatologists.

Authors:  Erkan Alpsoy; Burcin Cansu Bozca; Asli Bilgic
Journal:  Am J Clin Dermatol       Date:  2021-06-01       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.